Where’s Upton? 21st Century Cures Take Temporary Back Seat To The Internet
Executive Summary
Republicans dominate first official 21st Century Cures hearing, but Net Neutrality forces many members to choose, and the initiative’s leader makes quick exit.
You may also be interested in...
Drug Approval Reforms Ineffective Without Payer Reforms, Tunis Argues
Granting payers more conditional coverage authority may be necessary for legislation to succeed at accelerating biomedical innovation, the former CMS CMO argues, but industry may not be on board.
Congress Dives Into Biomedical Innovation: Will It Drown In A Deep Sea Of Competing Needs?
House Energy and Commerce committee says it’s committed to a bill to accelerate U.S. biomedical innovation before the next FDA user fee cycle, but the wide scope of needs and stakeholders may make crafting legislation challenging – never mind getting it passed.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.